On November 27, 2018 the BC Ministry of Health changed coverage of glatiramer products, GLATECTâ„¢ and COPAXONE®, which demonstrates a shift from previous public drug plan approaches for funding of subsequent entry products (biosimilars) for chronic diseases. Background GLATECTâ„¢ is the first subsequent entry glatiramer-based treatment available for reimbursement for RRMS in Canada – i.e. a follow on product to Copaxone®. It is classifed as a non-biological complex…